Loading...

Idorsia

DB:19T
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
19T
DB
CHF2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
19T Share Price and Events
7 Day Returns
-4.3%
DB:19T
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-18.3%
DB:19T
-9.2%
DE Biotechs
-6.7%
DE Market
19T Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Idorsia (19T) -4.3% 3.4% 10.1% -18.3% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 19T underperformed the Biotechs industry which returned -9.2% over the past year.
  • 19T underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

19T Value

 Is Idorsia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Idorsia. This is due to cash flow or dividend data being unavailable. The share price is €15.99.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Idorsia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Idorsia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:19T PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CHF CHF-3.10
SWX:IDIA Share Price ** SWX (2019-04-18) in CHF CHF18.26
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Idorsia.

DB:19T PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:IDIA Share Price ÷ EPS (both in CHF)

= 18.26 ÷ -3.10

-5.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idorsia is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Idorsia is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Idorsia's expected growth come at a high price?
Raw Data
DB:19T PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
5.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Idorsia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Idorsia's assets?
Raw Data
DB:19T PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CHF CHF5.07
SWX:IDIA Share Price * SWX (2019-04-18) in CHF CHF18.26
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:19T PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:IDIA Share Price ÷ Book Value per Share (both in CHF)

= 18.26 ÷ 5.07

3.6x

* Primary Listing of Idorsia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idorsia is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Idorsia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Idorsia has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

19T Future Performance

 How is Idorsia expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Idorsia expected to grow at an attractive rate?
  • Unable to compare Idorsia's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Idorsia's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Idorsia's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:19T Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:19T Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 5.9%
DB:19T Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 39.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:19T Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:19T Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 269 -334 -356 3
2022-12-31 285 -256 -408 1
2021-12-31 147 -450 -481 1
2020-12-31 29 -396 -409 2
2019-12-31 26 -529 -544 3
DB:19T Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2018-12-31 61 -353 -386
2018-09-30 209 -63 -213
2018-06-30 203 -25 -165
2017-12-31 190 115 -17
2016-12-31 -263 -335

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Idorsia is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Idorsia's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:19T Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Idorsia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19T Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.30 -0.35 -4.70 3.00
2022-12-31 -2.65 -1.38 -4.90 3.00
2021-12-31 -3.37 -1.72 -4.50 4.00
2020-12-31 -3.63 -2.48 -4.30 3.00
2019-12-31 -3.92 -3.16 -4.21 4.00
DB:19T Past Financials Data
Date (Data in CHF Millions) EPS *
2018-12-31 -3.10
2018-09-30 -1.75
2018-06-30 -1.37
2017-12-31 -0.15
2016-12-31 -2.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Idorsia will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Idorsia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Idorsia has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

19T Past Performance

  How has Idorsia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Idorsia's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Idorsia does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Idorsia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Idorsia's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Idorsia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Idorsia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19T Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 60.62 -386.39 60.64
2018-09-30 209.38 -213.19 66.39
2018-06-30 202.82 -164.88 63.89
2017-12-31 189.70 -17.12 37.14
2016-12-31 -335.14 40.20 16.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Idorsia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Idorsia has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Idorsia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Idorsia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Idorsia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

19T Health

 How is Idorsia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Idorsia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Idorsia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Idorsia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Idorsia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Idorsia Company Filings, last reported 3 months ago.

DB:19T Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 657.63 570.84 923.67
2018-09-30 769.74 568.81 803.07
2018-06-30 586.47 368.49 699.31
2017-12-31 739.51 364.68 840.75
2016-12-31 507.97 293.42 727.98
  • Idorsia's level of debt (86.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Idorsia's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Idorsia has sufficient cash runway for 2.5 years based on current free cash flow.
  • Idorsia has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 2.8% each year.
X
Financial health checks
We assess Idorsia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Idorsia has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

19T Dividends

 What is Idorsia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Idorsia dividends. Estimated to be 0% next year.
If you bought €2,000 of Idorsia shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Idorsia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Idorsia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:19T Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:19T Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Idorsia has not reported any payouts.
  • Unable to verify if Idorsia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Idorsia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Idorsia has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Idorsia's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Idorsia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Idorsia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Idorsia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

19T Management

 What is the CEO of Idorsia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Paul Clozel
AGE 63
CEO Bio

Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. Mr. Clozel serves as the Chief Executive Officer of Idorsia Ltd, a wholly-owned subsidiary of Actelion Ltd. He was a Practicing Cardiologist for 11 years, from 1974 to 1985. He served as the Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche for 12 years, from 1985 to 1997. He serves as a Director of Actelion Pharmaceuticals Ltd and Idorsia Ltd. He served as a Director of Actelion Ltd until June 16, 2017. He served as a Professor to the Chairman of Technical Innovation - Liliane Bet­tencourt at College de France, Paris, France for one year. Mr. Clozel holds a Medical Degree in France and obtained further training in Pharmacology and Physiology at the University of Montreal, Canada and the University of California, San Francisco.

CEO Compensation
  • Insufficient data for Jean-Paul to compare compensation growth.
  • Insufficient data for Jean-Paul to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Jean-Paul Clozel

TITLE
CEO & Director
AGE
63

André Muller

TITLE
Executive VP & CFO
AGE
55

Martine Clozel

TITLE
Executive VP & Chief Scientific Officer
AGE
63

Guy Braunstein

TITLE
Executive VP & Head of Global Clinical Development
AGE
62

Simon Jose

TITLE
Chief Commercial Officer
TENURE
0.3 yrs
Board of Directors

JP Garnier

TITLE
Chairman of the Board
AGE
71
TENURE
7.6 yrs

Jean-Paul Clozel

TITLE
CEO & Director
AGE
63

Bob Bertolini

TITLE
Director
AGE
57

John Greisch

TITLE
Director
AGE
63

David Stout

TITLE
Director
AGE
63

Viviane Monges

TITLE
Director
AGE
55
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Idorsia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Idorsia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

19T News

Simply Wall St News

19T Company Info

Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company has collaboration agreements with Johnson & Johnson to jointly develop and commercialize aprocitentan and its derivative compounds or products; Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy; and collaboration agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Details
Name: Idorsia Ltd
19T
Exchange: DB
Founded: 2017
CHF2,099,564,193
131,060,423
Website: http://www.idorsia.com
Address: Idorsia Ltd
Hegenheimermattweg 91,
Allschwil,
Basel-Landschaft, 4123,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX IDIA Common Shares SIX Swiss Exchange CH CHF 16. Jun 2017
OTCPK IDRS.F Common Shares Pink Sheets LLC US USD 16. Jun 2017
DB 19T Common Shares Deutsche Boerse AG DE EUR 16. Jun 2017
LSE 0RQE Common Shares London Stock Exchange GB CHF 16. Jun 2017
BATS-CHIXE IDIAZ Common Shares BATS 'Chi-X Europe' GB CHF 16. Jun 2017
Number of employees
Current staff
Staff numbers
650
Idorsia employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.